Inactive Instrument

Biocorrx Inc Stock Other OTC

US09073C1062

Healthcare Facilities & Services

BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Employees

Sector

Healthcare Facilities & Services

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	6.79M 5.91M 5.58M 5.07M 9.49M 651M 9.54M 66.7M 25.76M 331M 25.49M 24.92M 1.06B	P/E 2024	-0.78x	P/E 2025	-1.56x
Enterprise Value	8.79M 7.65M 7.22M 6.56M 12.29M 842M 12.35M 86.37M 33.36M 428M 33.01M 32.28M 1.38B	EV / Sales 2024	1,004x	EV / Sales 2025	11.4x
Free-Float	40.09%	Yield 2024 *	-	Yield 2025	-

09-10	Biocorrx Inc Announces Appointment of Richard J. Baum to Strategic Advisory Board	CI
09-04	BioCorRx Inc. Announces Resignation of Kate Beebe Devarney as Member of the Board of Directors, Effective August 31, 2026	CI
08-14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
01-06	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
11-15	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/07/25	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
15/05/25	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/03/25	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI

12-10	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
15/08/24	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
16/05/24	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
03/04/24	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
02/04/24	BioCorRx Reports Business Update for 2023	AQ

Manager	Title	Age	Since
Lourdes Felix CEO	Chief Executive Officer	58	09/11/2020
Louis Lucido PSD	President	77	05/01/2024

Director	Title	Age	Since
Lourdes Felix BRD	Director/Board Member	58	07/03/2013
Kent Emry CHM	Chairman	57	-
Louis Lucido BRD	Director/Board Member	77	01/03/2019

Biocorrx Inc Stock Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

Valuation: Biocorrx Inc

Latest news: Biocorrx Inc

Press Releases: Biocorrx Inc

Quotes and Performance

Managers and Directors: Biocorrx Inc

Other Healthcare Facilities & Services

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORRX INC	-15.84%	+6.09%	-	-	7.52M
CVS HEALTH CORPORATION	-1.58%	-6.77%	+20.05%	+25.36%	115B
HCA HEALTHCARE, INC.	-0.31%	+1.54%	+7.09%	+66.89%	92.89B
FRESENIUS SE & CO. KGAA	-0.05%	+3.15%	-2.92%	+54.59%	29.82B
QUEST DIAGNOSTICS INCORPORATED	-0.40%	+6.62%	+35.23%	+95.25%	27.31B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-1.13%	-2.02%	-7.43%	-6.40%	21.24B
TENET HEALTHCARE CORPORATION	+0.03%	-0.56%	+42.80%	+275.45%	21.09B
REDE D'OR SÃO LUIZ S.A.	+0.27%	-1.01%	-9.92%	+31.23%	15.7B
DAVITA INC.	+0.42%	+1.40%	+43.64%	+86.98%	11.68B
FRESENIUS MEDICAL CARE AG	-0.79%	+0.52%	-10.87%	-7.86%	11.87B
Average	-1.82%	+0.37%	+13.07%	+69.06%	38.56B
Weighted average by Cap.	-0.31%	-0.69%	+13.88%	+58.94%

	2024	2025
Net sales	7.66K 6.67K 6.3K 5.72K 10.72K 735K 10.77K 75.34K 29.1K 374K 28.79K 28.15K 1.2M	797K 694K 655K 595K 1.11M 76.43M 1.12M 7.84M 3.03M 38.87M 2.99M 2.93M 125M
Net income	-5.11M -4.45M -4.2M -3.81M -7.14M -489M -7.17M -50.19M -19.38M -249M -19.18M -18.75M -801M	-3.44M -3M -2.83M -2.57M -4.81M -330M -4.83M -33.81M -13.06M -168M -12.92M -12.63M -540M
Net Debt	2.72M 2.37M 2.23M 2.03M 3.8M 261M 3.82M 26.72M 10.32M 133M 10.21M 9.98M 426M	2M 1.74M 1.64M 1.49M 2.8M 192M 2.81M 19.67M 7.6M 97.59M 7.52M 7.35M 314M